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ABSTRACT
Objectives To develop a predictive model for pre-
eclampsia based on clinical risk factors for nulliparous
women and to identify a subgroup at increased risk, in
whom specialist referral might be indicated.
Design Prospective multicentre cohort.
Setting Five centres in Auckland, New Zealand; Adelaide,
Australia; Manchester and London, United Kingdom; and
Cork, Republic of Ireland.
Participants 3572 “healthy” nulliparous women with a
singletonpregnancyfromalargeinternationalstudy;data
on pregnancy outcome were available for 3529 (99%).
Main outcome measure Pre-eclampsia defined as
≥140 mm Hg or diastolic blood pressure ≥90 mm Hg, or
both, on at least two occasions four hours apart after
20 weeks’ gestation but before the onset of labour, or
postpartum, with either proteinuria or any multisystem
complication. Preterm pre-eclampsia was defined as
women with pre-eclampsia delivered before 37
+0 weeks’
gestation. In the stepwise logistic regression the
comparison group was women without pre-eclampsia.
Results Of the 3529 women, 186 (5.3%) developed pre-
eclampsia, including 47 (1.3%) with preterm pre-
eclampsia. Clinical risk factors at 14-16 weeks’ gestation
were age, mean arterial blood pressure, body mass index
(BMI), family history of pre-eclampsia, family history of
coronary heart disease, maternal birth weight, and
vaginal bleeding for at least five days. Factors associated
with reduced risk were a previous single miscarriage with
the same partner, taking at least 12 months to conceive,
high intake of fruit, cigarette smoking, and alcohol use in
the first trimester. The area under the receiver operating
characteristicscurve(AUC),underinternalvalidation,was
0.71. Addition of uterine artery Doppler indices did not
improve performance (internal validation AUC 0.71). A
framework for specialist referral was developed based on
a probability of pre-eclampsia generated by the model of
at least 15% or an abnormal uterine artery Doppler
waveform in a subset of women with single risk factors.
Nine per cent of nulliparous women would be referred for
a specialist opinion, of whom 21% would develop pre-
eclampsia. The relative risk for developing pre-eclampsia
and preterm pre-eclampsia in women referred to a
specialistcomparedwithstandardcarewas5.5and12.2,
respectively.
Conclusions The ability to predict pre-eclampsia in
healthy nulliparous women using clinical phenotype is
modest and requires external validation in other
populations. If validated, it could provide a personalised
clinical risk profile for nulliparous women to which
biomarkers could be added.
Trial registration ACTRN12607000551493.
INTRODUCTION
Pre-eclampsia is a multisystem complication that
occurs after 20 weeks of pregnancyand can cause con-
siderable maternal and fetal morbidity and mortality.
1
Thiscomplexconditionischaracterisedbysuboptimal
uteroplacental perfusion associated with a maternal
inflammatory response and maternal vascular endo-
thelial dysfunction.
2 One of the main reasons for serial
clinical assessment in antenatal care is the early detec-
tion of signs (raised blood pressure and proteinuria)
indicative of evolving pre-eclampsia.
3 Recent guide-
lines from the National Institute for Health and Clini-
cal Excellence (NICE) also recommend routine
screening for specific risk factors for pre-eclampsia
(nulliparity, older age, high body mass index (BMI),
family history of pre-eclampsia, underlying renal dis-
ease or chronic hypertension, multiple pregnancy,
more than 10 years between pregnancies, and a perso-
nal history of pre-eclampsia).
3 The expected rate of
pre-eclampsiawhenanyoneoftheseriskfactorsispre-
sent ranges from 3% to more than 30%, and many
women have several risk factors.
4-7 The absolute risk
for an individual will be determined by the presence
or absence of these and other predisposing or
protective factors not incorporated in the NICE
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8-13 Currently, because of a paucity of large
prospective studies, we cannot accurately estimate the
riskofpre-eclampsiafromcombinationsofclinicalrisk
factors.
414
In prospective studies of general obstetric popula-
tions, the reported performance of a limited number
of clinical risk factors to predict pre-eclampsia is mod-
est, with an AUC (area under the curve) in the order of
0.66 to 0.79.
1516 These cohorts included high risk
women and the best predictors of pre-eclampsia
(underlying medical conditions that predispose to pre-
eclampsia or a history of pre-eclampsia
4616) are not
applicable to healthy nulliparous women. Before pre-
ventive treatment and stratified antenatal care can be
offered to nulliparous women, we need to identify
those at high risk of pre-eclampsia.
1718 At present
there is no method to accurately stratify healthy nulli-
parous women according to their risk profile for pre-
eclampsia.
ThisstudyispartoftheSCOPE(ScreeningforPreg-
nancy Endpoints) study, a prospective, multicentre
cohort study of “healthy” nulliparous women with
the primary aim of developing screening tests to pre-
dict pre-eclampsia, infants who are small for gesta-
tional age, and spontaneous preterm birth. The study
design incorporates prospective collection of informa-
tiononallknownclinicalriskfactorsforpre-eclampsia.
The objectives are to develop multivariable predictive
modelsforpre-eclampsia(basedonclinicalriskfactors
present in early pregnancy alone or in combination
with ultrasound estimates of uteroplacental perfusion
and fetal measurements at 19-21 weeks’ gestation)and
determine their performance to predict pre-eclampsia
asa baselineforfuture externalvalidation; identifythe
rateofpre-eclampsiaassociatedwithspecificcombina-
tions of clinical risk factors and ultrasound scan vari-
ables; and develop a proposal for risk stratification of
“healthy” nulliparous women, based on combinations
ofkeyclinicalriskfactorsandscanindices,toidentifya
subgroup at increased risk of pre-eclampsia for whom
specialist referral might be indicated.
METHODS
Five centres (Auckland, New Zealand; Adelaide, Aus-
tralia; London and Manchester, UK; and Cork, Ire-
land) recruited nulliparous women with singleton
pregnancies to the SCOPE study between November
2004 and August 2008.
19
Women (n=4961) attending hospital antenatal
clinics, obstetricians, general practitioners, or commu-
nity midwives before 15 weeks’ gestation were invited
to participate. Exclusion criteria included recognised
as high risk of pre-eclampsia, small for gestational age
baby or spontaneous preterm birth because of under-
lyingmedicalconditions(chronichypertensionrequir-
ing antihypertensive drugs, diabetes, renal disease,
systemic lupus erythematosus, antiphospholipid syn-
drome, sickle cell disease, HIV), previous cervical
knife cone biopsy, three or more abortions or three
or more miscarriages, current ruptured membranes;
known major fetal anomaly or abnormal karyotype;
orinterventionthatcouldmodifytheoutcomeofpreg-
nancy (such as aspirin, cervical suture).
19 A research
midwife interviewed and examined women at 14-16
and 19-21 weeks’ gestation. Women underwent an
ultrasound scan at 19-21 weeks. At the time of inter-
view,datawereenteredonaninternetaccessedcentral
database with a complete audit trail (MedSciNet).
At 14-16 weeks’ gestation the following data were
collected:demographicinformationincludingage,eth-
nicity, immigration details, education, work, socioeco-
nomic index, income level, living situation; the
woman’s birth weight and gestation at delivery and
whether it was a singleton or multiple pregnancy; pre-
vious miscarriages, abortions, or ectopic pregnancies
and whether these pregnancies were with the same
partnerasthecurrentpregnancyornot;historyofinfer-
tility, use of assisted reproductive technologies, dura-
tion of sexual relationship, and exposure to partner’s
sperm; gynaecological (including polycystic ovarian
syndrome) and medical history, including hyperten-
sion while taking combined oral contraception,
asthma, urinary tract infection, inflammatory bowel
disease, thyroid disease, and thromboembolism; and
family history (in mother and sisters) of obstetric com-
plications (miscarriage, pre-eclampsia, eclampsia,
gestational hypertension, spontaneous preterm birth,
any preterm birth, gestational diabetes, stillbirth, and
neonatal death) and family history (mother, father, sib-
ling) of medical conditions (hypertension, coronary
artery heart disease, cerebrovascular accident, type 1
and 2 diabetes, and venous thromboembolism).
Information was collected on vaginal bleeding early
inpregnancy(gestation,severityanddurationofbleed-
ing,andrecurrentbleeds),hyperemesis,andinfections
during pregnancy. Vegetarian status was recorded,
and other dietary information before conception and
during pregnancy was obtained from food frequency
questions for fruit, green leafy vegetables, oily and
other fish, and fast foods. Use of folate and multivita-
mins, cigarettes, alcohol (including binge drinking),
andrecreationaldrugs(includingmarijuana,ampheta-
mine, cocaine, heroin, ecstasy, LSD (lysergide)) was
recorded for before conception, first trimester, and at
15 weeks. A lifestyle questionnaire was completed on
work, exercise and sedentary activities, snoring,
domestic violence, and social supports. Psychological
scales were completed to measure perceived stress,
20
depression,
21 anxiety,
22 and behavioural responses to
pregnancy(adaptedfromthebehaviouralresponsesto
illness questionnaire
23). Two consecutive manual
blood pressure measurements (mercury or aneroid
sphygmomanometer, with a large cuff if the arm cir-
cumference ≥33 cm and Korotkoff V for diastolic
blood pressure) were recorded. Other maternal mea-
surements included maternal height and weight and
waist, hip, arm, and head circumference. Proteinuria
in a midstream urine specimen was measured by dip-
stick or a protein:creatinine ratio. Random whole
blood glucose and serum lipid concentrations (trigly-
cerides,totalcholesterol,highdensitylipoproteincho-
lesterol, low density lipoprotein cholesterol, total
RESEARCH
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were also measured.
Ultrasound examination at 19-21 weeks’ gestation
included measurements of the fetus (biparietal dia-
meter,headcircumference,abdominalcircumference,
andfemurlength)andDopplerstudiesoftheumbilical
and uterine arteries.
24 All fetal measurements were
adjusted for gestational age by calculating the multiple
of the median for each gestational week. Mean uterine
resistance index (RI) was calculated from the left and
rightuterineresistanceindex.Ifonlyaleftorrightuter-
ine resistance index was available, this was used as
“meanresistanceindex”(n=20).Notchingofeachuter-
ine artery was recorded. An abnormal uterine artery
Doppler result was defined as a mean resistance
index >90th centile (>0.695).
Participants were followed prospectively, and
research midwives collected data on pregnancy out-
come and measurements of the baby. Data monitoring
included individual checks of all data for each partici-
pant,includingchecksforanytranscriptionerrorsofthe
lifestyle questionnaire, and detection of illogical or
inconsistentdataandoutlierswithcustomisedsoftware.
Primary outcome
Our primary outcome was pre-eclampsia defined as
systolic blood pressure ≥140 mm Hg or diastolic
blood pressure ≥90 mm Hg, or both, on at least two
occasions four hours apart after 20 weeks’ gestation
but before the onset of labour, or postpartum, with
either proteinuria (24 hour urinary protein ≥300 mg
or spot urine protein:creatinine ratio ≥ 30 mg/mmol
creatinine or urine dipstick protein ≥++) or any multi-
system complication of pre-eclampsia.
1925 Multisys-
tem complications included any of acute renal
insufficiency defined as a new increase in serum crea-
tinineconcentration≥100µmol/Lantepartumor>130
µmol/L postpartum; effects on liver, defined as raised
aspartate transaminase or alanine transaminase con-
centration, or both, >45 IU/L and/or severe right
upperquadrantorepigastricpainorliverrupture;neu-
rological effects included eclampsia, imminent
eclampsia (severe headache with hyper-reflexia and
persistent visual disturbance), or cerebral haemor-
rhage; and haematological effects included thrombo-
cytopenia (platelets <100×10
9/L), disseminated
intravascular coagulation, or haemolysis. The refer-
ence group was women who did not develop pre-
eclampsia.
Other definitions
The estimated date of delivery was calculated as fol-
lows: if the woman was certain of the date of her last
menstrualperiod(LMP),theestimateddateofdelivery
was adjusted only if a scan at <16 weeks’ gestation
found a difference of seven or more days between the
scangestationandthatcalculatedbytheLMPorascan
at20±1 weeksfounda difference of 10or more days.If
her date was uncertain, scan dates were used to calcu-
latetheestimateddateofdelivery.Pretermpre-eclamp-
sia was pre-eclampsia resulting in delivery before 37
+0
weeks’ gestation. Small for gestational age was defined
as a birth weight below the 10th customised centile,
adjustedformaternalheight,bookingweight,ethnicity,
and delivery gestation and infant’ss e x .
2627
Power calculation
The number of women required to be screened was
based on achieving suitable screening test characteris-
tics and precise estimates of their values. Given a pret-
est probability (prevalence) of pre-eclampsia of 5%,
then a post-test probability of 30% or greater would
make this a useful test, based on current clinical prac-
tice. The algorithmmust thereforehave sufficient abil-
ity such that it is unlikely the post-test probability will
fall below 0.30 (30%) for pre-eclampsia. This can be
attained, with a power of 80%, in a cohort of 3000 if
the true positive likelihood ratio of the screening test
is9.2to10.0.Givenaprevalenceof5%,ifweobservea
sensitivity of 90% this cohort size will give a 95% con-
fidenceintervalforthissensitivityof84.0to94.3,anda
specificity of 91%.
Datasets
We used two datasets to construct the predictive mod-
els for pre-eclampsia. The first comprised clinical vari-
ables obtained at 16-16 weeks’ gestation and the
second comprised clinical data at 14-16 weeks com-
bined with variables from the 19-21 week ultrasound
scan. Of the 933 original and derived variables
recorded, we excluded variables added after recruit-
ment commenced (n=76), paternal variables (n=48),
variablesnotapplicabletopredictionofpre-eclampsia
(n=246), variables with more than 10% missing data
(clinicallaboratorydataandworkvariablesnotapplic-
able to women not working, n=27), and 402 variables
with P>0.10 on univariable comparison of women
with and without pre-eclampsia. Of the remaining
134 variables, we selected 38 as candidate predictors
on the following criteria: known potential risk factors
for pre-eclampsia, ease of collection in the clinical set-
ting, and potential applicability to future populations
(see table A in appendix 1 on bmj.com for a full list of
variables). With this approach the only established
“risk” factor not included in the candidate predictors
was cigarette smoking, as in our dataset this was not
associated with pre-eclampsia. We added the number
of cigarettes smoked a day at 15 weeks’ gestation as a
candidate predictor, giving a total of 39 variables for
themultivariableanalysis.Variableswerenotincluded
ascandidatepredictorsbecauseofcolinearity(n=61),a
low cell count (<5) in the χ
2 test (n=11), lack of a con-
sistent relation with pre-eclampsia in literature (n=4),
or not readily applicable to a future obstetric popula-
tion (n=20).
Among the 39 candidate predictors, data were com-
plete in 32, missing in <1% for six variables, and miss-
ing in 6% for participant’s birth weight. We imputed
missing continuous data (n=4) with expectation maxi-
misationandusedthemedianforthreevariablesunre-
lated to other observed data. The expectation
maximisation algorithm was implemented in the
RESEARCH
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2829 To evaluate its
imputation, we used a permutation technique on the
complete dataset. For each variable, we systematically
removed each data point and imputed the “missing”
value using expectation maximisation. We calculated
the ratio of mean absolute error between imputed and
originalvaluestothemeanvalueforthatvariable.The
mean ratio for the variables imputed with expectation
maximisation was 10.8%.
Statistical methods
WeusedSAS(version9.1)forunivariabledataanalysis
and to generate a multivariable logistic regression
model. We used Student’s t test, Wilcoxon rank sum
test,orχ
2testforcomparingcharacteristicsinthestudy
population and pregnancy outcomes between women
who did and did not develop pre-eclampsia. Stepwise
logistic regression was used to determine independent
risk factors for pre-eclampsia in both datasets. The
order of variable selection was determined by the χ
2
statistic for each potential variable and the forward
selection step could be followed by removal of vari-
ables in one or more backward elimination steps. We
calculated receiver operating characteristics curves
and determined screening test characteristics at a
25%, 10%, and 5% false positive rate. For internal
validationweevaluatedthecalibrationanddiscrimina-
tion(10-foldcrossvalidation)ofthemodelusingmeth-
ods described by Altman et al.
30 Calibration was
assessed by plottingthe observed proportion of events
against the predicted probabilities. For the cross vali-
dation, participants were stratified by region (New
Zealand, Australia, Ireland, and UK), pre-eclampsia
status (positive or negative), and gestation (<260 days
or ≥260 days) and randomly allocated to one of
10 groups. Tenfold cross validation was then per-
formed, with 90% of the data used to generate a
model, and estimation of disease risk was performed
in the 10% remaining. These predicted values were
then combined across the 10 runs and summarised by
the C statistic (AUC). This entire procedure was
repeated 10 times.
To determine the variables most consistently
retained in the prediction models, we generated the
10 “best models,” based on the proportion of variance
explained, by calculating all possible logistic regres-
sion models retaining 10 variables. We determined
thefrequencyofeachvariablepresentinthe10highest
scoringmodelsandidentifiedkeyriskfactors.Wethen
calculatedtheproportionofwomenwithspecificcom-
binationsofkeyclinicalriskfactorsandabnormaluter-
ine artery Doppler at 20 weeks’ gestation who
developed pre-eclampsia.
RESULTS
Of the nulliparous women (n=4961) invited to partici-
pate in the study, 3780 (76%) agreed but a further 208
were excluded before or at the 15 week interview
(fig 1). Among the 3572 women recruited into the
study, we had data on pregnancy outcome for 3529
(99%). When we compared the women who declined
to participate (n=1202) with the 3529 women in the
study population there were minor but significant dif-
ferences in the ethnicity mix (79% v 87% white, 4% v
3%MaoriorPacificIslander,11%v7%Asian,6%v3%
other,P<0.001)andage(mean28.8(SD5.7)v28.1(SD
5.8), P=0.001). A further 182 women were excluded
Agreed to participate (n=3780)
Miscarriage or abortion (n=149)
Ineligible (n=38)
Declined consent (n=21)
Miscarriage or abortion 15-19+6 weeks (n=14)
Fetal death, anomalies, or premature rupture of
  membranes delivered at 20-21 weeks (n=11)
No Doppler scan at 20 weeks (n=157)
Recruited to study at 14-16 weeks (n=3572)
Study population at 14-16 weeks (n=3529)
Study population at 19-21 weeks (n=3347)
Ineligible status after recruitment (n=12)
Missing outcome data (n=31)
Fig 1 | Recruitment and flow of participants through study
Table 1 |Characteristics of participants at 14-16 weeks’ gestation by pre-eclampsia status.
Figures are numbers (percentages) unless stated otherwise
No pre-eclampsia
(n=3343)
Pre-eclampsia
(n=186) P value*
Mean (SD) maternal age (years) 28.2 (5.8) 27.0 (5.8) 0.004
Ethnicity:
White 2903 (87) 158 (85)
0.50
Maori or Polynesian 106 (3) 9 (5)
Asian 242 (7) 12 (6)
Other 92 (3) 7 (4)
Married/cohabiting 3080 (92) 172 (93) 0.87
Mean (SD) socioeconomic index 41 (17) 37 (16) <0.001
<12 years’ schooling 1581 (47) 98 (53) 0.15
Tertiary education 2670 (80) 140 (75) 0.13
Full/part time work 2798 (84) 148 (80) 0.16
Primigravida 2484 (74) 138 (74) 0.97
Previous miscarriage 487 (15) 28 (15) 0.83
Previous termination 463 (14) 22 (12) 0.51
Smoking status:
Non-smoker 2600 (78) 146 (78)
0.81 Stopped during pregnancy 371 (11) 22 (12)
Current smokers 372 (11) 18 (10)
BMI:
<20.0 58 (2) 1 (1)
<0.001
20.0-24.9 1830 (55) 70 (37)
25.0-29.9 936 (28) 55 (30)
≥30 519 (15) 60 (32)
Mean (SD) blood pressure (mm Hg):
Systolic 108 (11) 114 (11) <0.001
Diastolic 64 (8) 69 (8) <0.001
BMI=body mass index.
*For comparisons between groups with χ
2 or Student’s t test.
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missing data from the Doppler ultrasound (n=157)
(fig 1).
In total 186 (5%) women developed pre-eclampsia;
in eight the diagnosis was postpartum and 47 (1%)
deliveredpreterm.Table 1showsbackgroundcharac-
teristics and table 2 shows outcomes of pregnancy in
women who did and did not develop pre-eclampsia.
Women who developed pre-eclampsia were younger,
had a lower socioeconomic index, and at 15 weeks’
gestationweremorelikelytobeobeseandhavehigher
blood pressure. Pre-eclampsia developed at a mean of
36.9 (SD 3.3) weeks’ gestation, with a median protein:
creatinine ratio of 88 mg/mmol (range 30-2445 mg/
mmol) and 24 hour urinary protein excretion of
0.78 g (range 0.30-9.9g). The diagnosisof pre-eclamp-
sia was based on hypertension in combination with
multisystem complications in 24 of the 186 women
(13%), four of whom had “+” proteinuria. Forty two
per cent of the women had at least one multisystem
complication: 8% (n=14) had a diagnosis of HELLP
(haemolysis,elevatedliverenzymes,andlowplatelets)
orELLP(elevatedliverenzymesandlowplatelets),5%
(n=9) developed impaired renal function, and one
woman had eclampsia. A quarter of the babies were
born preterm and 24% were small for gestational age.
Prediction of pre-eclampsia with clinical risk factors and
uterine artery Doppler
Table 3 shows the clinical risk factors independently
associated with pre-eclampsia on multivariable analy-
sis(see tablesB1 and B2 in appendix2 onbmj.com for
unadjusted odds ratios). Addition of ultrasound scan
variables to the 15 week clinical data resulted in age
and the number of cigarettes a day being removed
from the model and inclusion of duration of sexual
relationship of six months or less and uterine artery
Doppler waveform indices. Based on clinical risk fac-
tors, the mean AUC from the ten 10-fold cross valida-
tions was 0.71 (SE 0.002) (fig 2). The AUC for the
proposedmodelbasedontheobservationsusedtocre-
ate the model was 0.76, indicating a bias in the C sta-
tistic of about 5%. The addition of 20 week uterine
artery Doppler indices did not improve performance
based on the study population (internally validated
AUC 0.71 (SE 0.003)). Figure 3 shows that the model
has a reasonable level of calibration, but there is an
indication that, at the higher probabilities for pre-
eclampsia, it might underestimate cases.
Table 4 summarises the screening characteristics of
the models at a false positive rate of 5%, 10%, and 25%
based on the women from whom the model was cre-
ated and from the internal validation where the values
reported are the means of those derived from each of
the cross validation analyses.
Toestimateawoman’sprobabilityofpre-eclampsia,
a risk score can be calculated based on the formulas in
the footnote of table 3. The predicted probability
of pre-eclampsia can then be calculated from
1/(1+e
−riskscore).
31 For example, for a 28 year old nulli-
parous woman whose birth weight was 2400 g, with
a mean arterial pressure of 96 mm Hg, BMI 30, a
family history of pre-eclampsia, and no protective fac-
tors, her probability of pre-eclampsia is 39%. Her risk
of pre-eclampsia decreases as each risk factor is
removed in stepwise fashion; if her mean arterial pres-
sure is 80 mm Hg her probability of pre-eclampsia
would be 18%, if her BMI was 24 her probability
would be 14%, if she had no family history of pre-
eclampsia her probability would be 8%, and if her
birth weight had been 3500 g her probability would
be 5%. If she had protective factors, such as a previous
early miscarriage with her partner, her risk would be
reduced to 2%.
Impact of definition of pre-eclampsia
To evaluate the impact of 24 women receiving a diag-
nosis of pre-eclampsia based on the presence of gesta-
tional hypertension combined with multisystem
complications, the model was reconstructed defining
Table 2 |Characteristics of pregnancy outcomes by pre-eclampsia status. Figures are
numbers (percentages) unless stated otherwise
No pre-eclampsia
(n=3343)
Pre-eclampsia
(n=186) P value*
Maternal
Mean (SD) blood pressure (mm Hg):
Systolic 122 (13) 164 (18) <0.001
Diastolic 75 (10) 104 (10) <0.001
Fetal
No of infants 3329† 186
Mean (SD) birth weight (g) 3408 (581) 3033 (809) <0.001
Mean (SD) gestation at delivery (weeks) 39.5 (2.7) 37.9 (2.8) <0.001
SGA (<10th customised centile)‡ 332 (10) 44 (24) <0.001
Preterm birth:
<37 weeks 214 (6) 47 (25) <0.001
<34 weeks 76 (2) 19 (10) <0.001
Admission to neonatal unit 349 (11) 57 (31) <0.001
Perinatal death 18 (0.5) 1 (0.5) 1.0
SGA=small for gestational age.
*P values are comparisons between groups with χ
2 or Student’s t test.
†Excludes miscarriages and abortions.
‡For 3327 women in “no pre-eclampsia” group as customised centiles unavailable when fetus died in utero
before 20 weeks’ gestation.
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Fig 2 | Receiver operating characteristics curves based on
independent predicted values from ten 10-fold cross
validation runs of model of clinical risk factors at 15 weeks
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(n=162). Most risk factors and protective factors
remained with similar odds ratios, except that age,
high intake of fruit, and cigarettes were excluded and
a sexual relationship of six months or less (odds ratio
1.7, 95% confidence interval 1.05 to 2.7), hyperemesis
at 15 weeks (2.0, 1.1 to 3.7), and maternalheight (0.87,
0.76 to 1.0) per 5 cm increase) were included.
Reproducibility of prediction model
To investigate the stability and potential reproducibil-
ityofthemodel(usingallcandidatepredictors)wecon-
structed 10 “best models” that included 10 variables.
The risk factors (mean arterial blood pressure, BMI,
family history of pre-eclampsia, family history of cor-
onary heart disease (woman’s father), participant’s
birth weight) and protective factors (≥12 months to
conceive, alcohol used in the first trimester) occurred
in all “10 best models.” Of the other variables in our
model (table 3), six occurred in three to seven of the
best models, while cigarettes a day was not selected by
the stepwise model fitting procedure.
Risk estimates with specific combinations of clinical risk
factors
Table 5 shows the proportion of women with specific
combinations of key clinical risk factors and abnormal
result on uterine artery Doppler who developed pre-
eclampsia. We have shown systolic blood pressure
ratherthanmeanarterialbloodpressureasthatrequires
calculation and, unless incorporated into an algorithm,
is not easily applied in a routine clinic setting.
Specialist referral framework for nulliparous women
To better understand potential clinical implications,
we developed a framework for specialist referral in a
population (n=1000) based on observations in our
study population (fig 4). In the first stage, women
Table 3 |Clinical risk factors at 15 weeks and ultrasound scan variables at 20 weeks included in logistic regression model for pre-eclampsia
Clinical risk factors at 15 weeks* Plus ultrasound scan at 20 weeks†
No pre-eclampsia
(n=3343)
Pre-eclampsia (n
=186)
Adjusted OR
(95%CI)
No pre-eclampsia
(n=3167)
Pre-eclampsia
(n=180)
Adjusted OR
(95%CI)
Risk factors‡ ‡
Decrease of 5 years in age 28.2 (5.8) 27 (5.8) 1.2 (1.1 to 1.4) —— —
Increase of 5 mm Hg in MAP§ 78 (8) 84 (8) 1.4 (1.3 to 1.5) 78 (8) 84 (8) 1.4 (1.2 to 1.5)
Increase of 5 in BMI 25.4 (5.1) 28.2 (6.7) 1.3 (1.1 to 1.4) 25.4 (5.1) 28.3 (6.8) 1.3 (1.1 to 1.5)
Family history of pre-eclampsia 309 (9%) 35 (19%) 2.0 (1.3 to 3.0) 299 (9%) 35 (19%) 1.9 (1.3 to 2.9)
Family history of coronary heart disease¶ 384 (12%) 35 (19%) 1.9 (1.2 to 2.8) 359 (11%) 35 (19%) 1.8 (1.2 to 2.8)
Decrease of 500 g in woman’s birth weight** 3293 (552) 3177 (540) 1.2 (1.1 to 1.4) 3292 (551) 3177 (547) 1.2 (1.1 to 1.4)
Vaginal bleeding ≥5 days 125 (4%) 13 (7%) 2.0 (1.1 to 3.8) 116 (4%) 12 (7%) 1.9 (1.0 to 3.7)
≤ 6 months in sexual relationship† † ——— 256 (8%) 26 (14%) 1.7 (1.04 to 2.6)
Bilateral notches ——— 327 (10%) 33 (18%) 1.7 (1.1 to 2.6)
Increase of 0.1 in mean uterine artery RI ——— 0.56 (0.10) 0.60 (0.12) 1.2 (1.04 to 1.5)
Protective factors
One miscarriage ≤10 weeks, same partner 301 (9%) 8 (4%) 0.45 (0.22 to 0.93) 284 (9%) 8 (4%) 0.44 (0.21 to 0.92)
≥12 months to conceive 384 (12%) 12 (7%) 0.40 (0.22 to 0.75) 357 (11%) 12 (7%) 0.41 (0.22 to 0.76)
High fruit intake (≥3/day) 1347 (40%) 52 (28%) 0.69 (0.49 to 0.98) 1266 (40%) 48 (27%) 0.65 (0.45 to 0.92)
Alcohol consumption 1st trimester 1705 (51%) 69 (37%) 0.60 (0.44 to 0.83) 1616 (51%) 65 (36%) 0.57 (0.41 to 0.79)
Increase of 5 cigarettes/day 0.8 (3.0) 0.6 (2.4) 0.73 (0.53 to 1.0) —— —
MAP=mean arterial pressure, BMI=body mass index, RI=uterine resistance index.
*Risk score for pre-eclampsia from logistic regression model based on clinical risk factors is calculated as −6.8855−0.0393×age+0.0659×MAP+0.0483×BMI+0.6861×family history of pre-
eclampsia+0.6232×family history of coronary heart disease−0.3881×participant’s birth weight (kg)+0.7129×vaginal bleeding ≥5 days−0.8033×one miscarriage ≤10 weeks, same partner
−0.9070×≥12 months to conceive−0.3733×high fruit intake at 15 weeks−0.508×alcohol consumption in first trimester−0.063×No of cigarettes/day at 15 weeks.
†Risk score for pre-eclampsia from logistic regression model based on clinical risk factors and ultrasound scan data calculated as −9.1113+0.0634×MAP+ 0.0485×BMI+0.6539×family history
of pre-eclampsia+0.6093×family history of coronary heart disease−0.3787×participant’s birth weight (kg)+0.6493×vaginal bleeding ≥5 days+0.5008×months in sexual relationship ≤6 months
+0.5084×bilateral notches+2.0802×mean uterine artery RI− 0.8248×one miscarriage ≤10 weeks, same partner−0.8983×≥12 months to conceive−0.4389×high fruit intake at 15 weeks
−0.5573×alcohol consumption in first trimester.
‡Variable name (unit change for adjusted odds ratio (OR).
§MAP calculated from second blood pressure measurement at 14-16 weeks.
¶Participant’s father had coronary heart disease.
**Because of missing data numbers for woman’s birth weight were 3145, 174, 2993, and 168, respectively.
††≤6 months in sexual relationship with father of baby before conceiving.
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Fig 3 | Observed rate of pre-eclampsia compared with
predicted probabilities of pre-eclampsia based on clinical risk
factors model
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of pre-eclampsia generated by the model was at least
15%.Amongthosenotreferred,womenwithasystolic
blood pressure >120 mm Hg, a BMI ≥30, or a family
history of pre-eclampsia underwent a uterine Doppler
ultrasound with their fetal anatomy scan at 20 weeks,
and those with an abnormal uterine artery resistance
index also had a specialist referral. Of the women
referred for a specialist opinion, 21% developed pre-
eclampsia and 8% developed preterm pre-eclampsia.
Therelativeriskfordevelopingpre-eclampsiaandpre-
term pre-eclampsia in the specialist referred group
compared with standard care group was 5.5 and 12.2,
respectively.
Overall, application of this framework for specialist
referral would result in 34% of women with pre-
eclampsia (63 of 186) and 53% of those who develop
preterm pre-eclampsia (25 of 47) being referred. If the
referral criteria did not include uterine Doppler, fewer
cases of preterm pre-eclampsia (16 of 47, 34%) would
be detected. These results also show that negative pre-
diction based on clinical risk assessment, with or with-
out Doppler ultrasonography, is too inaccurate to
allow a reduction in antenatal care.
DISCUSSION
In this large prospective international cohort of
“healthy” nulliparous women an algorithm for pre-
eclampsia, which included clinical risk factors at
15 weeks’ gestation, had moderate predictive perfor-
mance. The algorithm included well recognised risk
factors (blood pressure, BMI, and a family history of
pre-eclampsia)alongwithlessestablishedfactors,such
as prolonged vaginal bleeding, maternal low birth
weight,andthewoman’sfatherhavingcoronaryartery
disease. The algorithm had moderate predictive per-
formance—theareaunderthereceiveroperatingchar-
acteristics curve (AUC) was 0.76—and detected 37%
and 61% of women who developed pre-eclampsia
with a false positive rate of 10% and 25%, respectively.
Additionofinformationfromultrasonographydidnot
significantly improve performance of the algorithm,
withanAUCof0.77.Wewouldexpectpoorerscreen-
ing performance of the algorithm in other nulliparous
populations,asevidentbytheAUCof0.71oninternal
validation. Given the prospective design, cohort size,
comprehensive range of candidate predictors, high
quality data, and completeness of follow-up, this is
likely to be indicative of the best performance achiev-
able using clinical and ultrasonography data to predict
pre-eclampsia in a “healthy” nulliparous population.
To considerably improve prediction performance
will require either the development of specific clinical
risk algorithms for disease subtypes, such as preterm
andtermpre-eclampsia,ortheadditionofbiomarkers,
or both.
The concept of a personalised clinical risk estimate
fordisease,towhichbiomarkerscanbeadded,isestab-
lished in several areas of medicine. The algorithm to
predict pre-eclampsia reported here provides a first
step towards a personalised risk score for pre-eclamp-
sia among nulliparous women. It is inevitable the
modelwillbeoverfittedtoourpopulationandexternal
validation of the algorithm in other nulliparous popu-
lationsisessential.Weplantoevaluateitsperformance
in the next3000 womenrecruitedinto SCOPE,nearly
all of whom will be recruited in different centres than
the initial 3500 women. Validation should also be per-
formed in other study populations of nulliparous
women.
Strengths and weaknesses
A major strength of this study is its large multicentre
prospective design with excellent follow-up. As the
focus of the SCOPE study is development of tests to
predict pregnancy outcome with potential to translate
into clinical care, we recruited a clearly defined popu-
lationofnulliparouswomen,enablingidentificationof
similar populations for external validation. This is cri-
ticalforgeneralisabilityofariskassessmentalgorithm;
the population in which the algorithm is developed
needs to be identifiable if a screening test is to be used
in clinical care.
32
Weobtainedhighqualitydataforallknownriskfac-
tors for pre-eclampsia from questionnaires adminis-
tered at interviews, along with detailed standard
operating procedures. Use of a real time database,
with automated checking procedures, reduced data
entry errors and transcription errors. For a dataset of
this size, the rate of missing data was minimal. The
Table 4 |Prediction of pre-eclampsia from algorithms based on clinical risk factors at 14-16 weeks’ gestation in cohort and independent predicted values
from ten 10-fold cross validation runs. Values are shown with 95% confidence intervals
No (%) with abnormal test result Sensitivity Specificity
Positive predictive
value
Negative predictive
value Positivelikelihoodratio Negativelikelihoodratio
Training cohort*
218 (6) 27 (22 to 34) 95 (94 to 96) 24 (22 to 25) 96 (95 to 97) 5.5 (4.2 to 7.2) 0.76 (0.70 to 0.84)
403 (11) 37 (30 to 44) 90 (89 to 91) 17 (16 to 18) 96 (96 to 97) 3.6 (2.9 to 4.5) 0.71 (0.63 to 0.79)
949 (27) 61 (54 to 68) 75 (74 to 76) 12 (11 to 13) 97 (97 to 98) 2.5 (2.2 to 2.8) 0.52 (0.43 to 0.62)
Ten 10-fold cross validation† †
205 (6) 20 (18 to 22) 95 (95 to 95) 18 (16 to 20) 96 (95 to 96) 3.9 (3.5 to 4.4) 0.85 (0.83 to 0.87)
392 (11) 30 (28 to 33) 90 (89 to 91) 14 (13 to 16) 96 (96 to 96) 3.0 (2.8 to 3.3) 0.78 (0.75 to 0.80)
935 (27) 53 (48 to 58) 75 (74 to 76) 10 (10 to 12) 97 (96 to 97) 2.1 (1.9 to 2.3) 0.63 (0.56 to 0.70)
*Based on clinical risk factor algorithm from table 2 using cut-offs at 5%, 10%, and 25% false positive rates
†Average test characteristics across 10 different cross validation repeats.
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dataintegrity.Potentialmeasurementerrors,suchasin
selfreportedfamilyhistory,
33couldhaveoccurred,but
as the goal was to develop a prototype algorithm ulti-
mately for clinical use, this limitation was accepted.
Principal investigators reviewed outcome data for
cases, ensuring accurate diagnosis. One of the chal-
lenges when predicting rare events in prospective
cohorts,such as SCOPE, is the relatively low numbers
of cases compared with studies based on huge epide-
miological databases. While the latter might have a
substantially greater number of events, their inter-
pretation is restrained by less accurate diagnosis.
Thereisnoconsensusastothebestmethodforselec-
tion of variables.
31 Given the rich dataset of potential
predictors for pre-eclampsia, we used a pruning step
basedonsignificancetestingandthenselectedasubset
of candidate variables on a priori knowledge. This
could have introduced variable selection bias, but it is
reassuring that the clinical risk factors and their
strength of association with pre-eclampsia are consis-
tentwiththeliterature.Whilewecouldundertakeonly
internal validation at this stage, external validation is
planned.
Comparisons with other studies
Previous studies investigating risk factors for pre-
eclampsia have used birth registries or hospital
databases,
634 randomised trials with negative results
(that is, no treatment effect shown),
3536 and, in a few
studies, prospective cohorts (usually general obstetric
populations) designed to investigate outcomes of
pregnancy.
9121337Consistentwithothercontemporary
studies, the women who developed pre-eclampsia
were younger, more obese, and more likely to have
lower socioeconomic status.
37-39
Many of the risk factors included in the algorithm
presented here are associated with a similar degree of
risk to that previously reported, giving confidence
regarding the potential applicability of the algorithm
to other populations. Higher blood pressure within
the normal range, a higher BMI, and a family history
of pre-eclampsia had similar predictive characteristics
to those observed in other studies.
839-41 In our algo-
rithm, blood pressure was the most important risk fac-
tordrivingtheestimatedprobabilityofpre-eclampsia.
9
Meanarterialpressure,ratherthan systolicor diastolic
bloodpressureblood,wasselectedbystepwiselogistic
regression and included in the model.
8 If it was imple-
mented into clinical practice, the clinician would
derivethemeanarterialpressurefromsystolicanddia-
stolicbloodpressureenteredintothe algorithm.Ahis-
tory of coronary artery disease in the woman’s father
wasassociatedwitha1.9-foldincreaseintheriskofpre-
eclampsia, consistent with a previous report and the
association between pre-eclampsia and subsequent
Table 5 |Probability of pre-eclampsia in presence of combinations of clinical risk factors at 15 weeks* and uterine artery Doppler at 20 weeks†
No of women
Systolic BP
>120 mm Hg BMI ≥30 FH PE†
FH coronary
artery disease
Maternal birth
weight <2500 g
Vaginal bleeding
≥5 days
Abnormal mean
uterine artery RI
Proportion PE %
(95% CI)
Proportion
preterm PE %
(95% CI)
310 ● —— — — — — 14 (10 to 18) 5 (3 to 8)
579 — ● —— — — — 10 (8 to 13) 2 (1 to 4)
344 —— ● ———— 10 (7 to 14) 3 (2 to 6)
419 —— — ● ——— 8( 6t o1 1 ) 3( 2t o5 )
224 —— — — ● —— 9( 6t o1 3 ) 3( 2t o6 )
138 —— — — — ● — 9( 6t o1 6 ) 1( 0 . 4t o5 )
131 ●● —— — — — 16 (11 to 23) 4 (2 to 9)
46 ● — ● ———— 20 (11 to 33) 7 (2 to 18)
52 ● —— ● ——— 15 (8 to 28) 8 (3 to 18)
21 ● —— — ● —— 33 (17 to 55) 24 (11 to 45)
15 ● —— — — ● — 27 (11 to 52) 13 (4 to 38)
73 — ●● ———— 18 (11 to 28) 7 (3 to 15)
77 — ● — ● ——— 14 (8 to 24) 4 (1 to 11)
41 — ● —— ● —— 17 (9 to 31) 5 (1 to 16)
24 — ● —— — ● — 8( 2t o2 6 ) —
12 —— ● —— ● — 42 (19 to 68) —
24 —— — ●●—— 17 (7 to 36) 8 (2 to 26)
326 —— — — — — ● 10 (7 to 14) 6 (4 to 9)
29 ● —— — — — ● 24 (12 to 42) 14 (6 to 31)
65 — ● —— — — ● 17 (10 to 28) 11 (5 to 21)
44 —— ● ——— ● 16 (8 to 29) 16 (8 to 29)
32 —— — ● ——● 13 (5 to 28) 6 (2 to 20)
25 —— — — — ●● 8( 2t o2 5 ) —
33 —— — — ● — ● 9( 3t o2 4 ) 9( 3t o2 4 )
BP=blood pressure; FH=family history; PE=pre-eclampsia; RI=resistance index.
*In 3529 women; 5% developed pre-eclampsia and 1% developed preterm pre-eclampsia.
†In 3347 women; abnormal result=uterine artery RI >0.695 or bilateral notches.
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4243Confirmingtheresultsofa
case-controlstudy,
44alowermaternalbirthweightwas
associatedwithanincreasedriskofpre-eclampsia,with
an even greater risk when low maternal birth weight
coexisted with other key risk factors. Prolonged vagi-
nal bleeding in early pregnancy was associated with a
twofold increase in risk of pre-eclampsia. As reported
by others, most of these bleeds were mild in severity,
suggesting that a discrete bleeding pattern could be
associated with later pre-eclampsia.
45
Severalfactorswereassociatedwithareducedriskof
pre-eclampsia. A single early miscarriage with the
same partner, eating a lot of fruit, and smoking were
protective, again reassuringly consistent with previous
reports.
101246 The protective influence of cigarette
smoking in our cohort was less than previously
reported, and cigarettes did not remain in the model
whenweaddeduterinearteryDopplerindices.
46Alco-
holuseinthefirsttrimesterwasprotectivebutrequires
confirmation in other cohorts.
47 Obese women are
reported to drink less alcohol, possibly because food
fulfilstheiraddictivebehaviour.
4849Obesityisunlikely
to be the only explanation, however, as the protective
effectofalcoholisretainedwithBMIinthemodel,and
there was no interaction between BMI and alcohol.
A recent series of publications reported algorithms
to predict pre-eclampsia based on clinical risk factors
in a general population comprising high risk women
(previous pre-eclampsia and medical conditions), nul-
liparouswomen,andlow riskwomen(multiparaswith
previous uncomplicated pregnancies).
93650A model is
fitted to the population in which it was developed,
using the available candidate predictors.
30 A general
antenatal population constructed of subgroups with
different risk profiles is difficult to replicate and future
“generalpopulations”arelikelytocompriseadifferent
case-mix. The importance of population differences is
evidentinthefailureofoneproposedalgorithmtovali-
date in a high risk population,
51 raising questions as to
moregeneralapplicabilitytootherpopulationssuchas
“healthy” nulliparous women. Poor performance on
validation might also occur because key predictors
aremissingfromthemodel.Whenthelistofcandidate
predictors includes strongly predictive factors, such as
previous pre-eclampsia, renal disease, and chronic
hypertension,
1634thesewilltakeprecedence,replacing
other factors that might be more relevant to healthy
nulliparous women. In contrast, in SCOPE, we inves-
tigated candidate predictors applicable to healthy nul-
liparous women.
Clinical relevance
The new information on the rate of pre-eclampsia in
the presence of combinations of specific risk factors
(table 5)couldbeusedbyclinicianstoimprovecurrent
guidelinesforspecialistreferralinnulliparouswomen.
When we applied the criteria proposed in the NICE
guidelines to the SCOPE cohort, 16.5% of nulliparous
women would be referred for a specialist opinion of
whom 10% would develop pre-eclampsia.
52 This
included 31% of the 186 women who developed pre-
eclampsia and 38% of the 47 of those who developed
preterm pre-eclampsia. If we included only first preg-
nancy, as in the NICE guidelines,
52 12% would be
referred and 23% and 28% cases of pre-eclampsia and
preterm pre-eclampsia, respectively, would be
detected.Ourproposedframeworkforspecialistrefer-
ral based on the algorithm, along with uterine artery
Doppler screening of a subpopulation, performed bet-
ter than the NICE guidelines but requires validation.
Amongthereferredwomen(9%ofnulliparas),therate
ofpre-eclampsiawas21%.Thirtyfourpercentofcases
of pre-eclampsia and 53% of cases of preterm pre-
eclampsia were identified. This framework has the
potential to identify a subgroup of nulliparous
womenathighriskofpre-eclampsiawhocouldbenefit
from low dose aspirin and more intensive antenatal
surveillance. It does not, however, provide additional
information for the rest, whose risk is similar to an
unscreened nulliparous population. Hence a negative
“test” result would not modify current clinical care.
The algorithm requires external validation, followed
by assessment of the impact of increased surveillance,
thefalsepositiveandfalsenegativeresults,andahealth
economics analysis. If externally validated, this algo-
rithm could help to inform future NICE guidelines
for specialist referral. It could be made accessible,
includingviatheweb,asasupportforriskstratification
ofhealthynulliparouswomeninlowresourcesettings.
To improve overall accuracy and detection of cases,
the clinical algorithm will require the addition of bio-
markers.
Conclusions
Wehaveidentifiedthemostimportantclinicalriskfac-
tors for pre-eclampsia in healthy nulliparous women
andprovidednewinformationonthelevelofriskasso-
ciated with specific combinations of risk factors. The
predictive performance of the algorithm is modest,
but offers a considerable improvement on current
practice in healthy nulliparous women. As all known
risk factors were included in this large prospective
Standard care
(913 women, 4% develop pre-eclampsia,
0.7% preterm pre-eclampsia)
No scan 0.1%
Normal uterine
resistance index
20%
Abnormal uterine
resistance index
3%
Specialist referral
(87 women, 21% develop pre-eclampsia,
8% preterm pre-eclampsia)
Nulliparous women (n=1000, 5.3% develop pre-eclampsia  and 1.3% preterm pre-eclampsia)
Step 1
Combinations of clinical
risk factors with ≥15% risk
of pre-eclampsia (6%)
Step 2
If systolic blood pressure
>120 or BMI ≥30 or family
history of pre-eclampsia
and not in Step 1 (23%)
20 week uterine artery Doppler
with fetal anatomy ultrasound
Step 3
No risk factors (71%)
Fig 4 |Framework for specialist referral when estimated risk of pre-eclampsia is ≥15% in model
or presence of clinical risk factor with abnormal result on uterine artery Doppler scan
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tionsofusingclinicalphenotypetopredictpre-eclamp-
sia. The algorithm serves as a prototype that requires
validation in other nulliparous populations. If vali-
dated,it mightprovidea personalisedclinicalrisk pro-
file for nulliparous women to which biomarkers could
be added.
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